CAY 001
Alternative Names: CAY-001Latest Information Update: 16 Mar 2022
At a glance
- Originator Cayuga Biotech
- Class Anticoagulants; Antihaemorrhagics; Polyphosphates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Blood coagulation disorders
- Research Haemorrhage; Wounds
Most Recent Events
- 03 Mar 2022 Early research in Blood coagulation disorders in USA (SC), prior to March 2022 (Cayuga Biotech pipeline, March 2022)
- 03 Mar 2022 Early research in Haemorrhage in USA (IV), prior to March 2022 (Cayuga Biotech pipeline, March 2022)
- 03 Mar 2022 Early research in Wounds in USA (Topical), prior to March 2022 (Cayuga Biotech pipeline, March 2022)